Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Rheumatoid arthritis (RA) is common and leads to joint damage due to persistent synovitis. The persistence of inflammation is maintained by hyperplastic stromal tissue, which drives the accumulation of leukocytes in the synovium. Aggressive treatment after the first 3-4 months of symptoms, with either disease modifying anti-rheumatic drugs or anti-tumor necrosis factor (TNF)-alpha therapy, reduces the rate of disease progression. However, it rarely switches off disease such that remission can be maintained without the continued need for immunosuppressive therapy. There is increasing evidence that the first few months after symptom onset represent a pathologically distinct phase of disease. This very early phase may translate into a therapeutic window of opportunity during which it may be possible to permanently switch off the disease process. The rationale for, and approaches to, treatment within this very early window are discussed.

Original publication

DOI

10.1016/j.berh.2006.05.005

Type

Journal article

Journal

Best Pract Res Clin Rheumatol

Publication Date

10/2006

Volume

20

Pages

849 - 863

Keywords

Antibodies, Antirheumatic Agents, Apoptosis, Arthritis, Rheumatoid, Disease Progression, Humans, Leukocytes, Neutrophils, Peptides, Cyclic, Remission Induction, Rheumatoid Factor, Synovitis, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha